[go: up one dir, main page]

TW201008572A - Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same - Google Patents

Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same Download PDF

Info

Publication number
TW201008572A
TW201008572A TW97131705A TW97131705A TW201008572A TW 201008572 A TW201008572 A TW 201008572A TW 97131705 A TW97131705 A TW 97131705A TW 97131705 A TW97131705 A TW 97131705A TW 201008572 A TW201008572 A TW 201008572A
Authority
TW
Taiwan
Prior art keywords
grass
lung cancer
fragrant
substance
preparing
Prior art date
Application number
TW97131705A
Other languages
Chinese (zh)
Other versions
TWI392500B (en
Inventor
Xia-Fen Xu
Zhe-Ying Hong
yong-chang Wu
Original Assignee
Xia-Fen Xu
Zhe-Ying Hong
yong-chang Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xia-Fen Xu, Zhe-Ying Hong, yong-chang Wu filed Critical Xia-Fen Xu
Priority to TW97131705A priority Critical patent/TW201008572A/en
Publication of TW201008572A publication Critical patent/TW201008572A/en
Application granted granted Critical
Publication of TWI392500B publication Critical patent/TWI392500B/zh

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to an anti-lung cancer Glossogyne tenuifolia substance and a method of preparing the same. The preparation method comprises solvent extraction of Glossogyne tenuifolia, followed by separation method like column chromatography, high performance chromatography, and the likes. As such, compound and composition capable of preventing or inhibiting growth of lung cancer cells can be prepared. In addition, thins invention also discloses an application method of the anti-lung cancer substance.

Description

201008572 .九、發明說明: 【發明所屬之技術領域】 本發明係有關一種香茹草抗姑、伊 如早沉肺癌物質及其製備方法, 更詳而言之,特別係指將湃ό备 將源自香茹草(Glossogyne tenui folia)中的抗肺癌生物活蚀犏 性物質,透過溶劑萃取、 .管柱層析、高效管柱層析等方式 从褽備出,能用以抑制 或預防肺癌細胞生長。 【先前技術】 ©#癌為-治癒率低且治癒後又極易復發之癌症,其治 療方法包括:外科療法、放射療法與化學療法等,其中仍 以化學療法為i,再輔以與手#及放射治療等混合應用, 以防止癌腫轉移、復發,以提高長期生存率。因此,開發 ' 新的抗肺癌化合物將有助於改善化學療法的效果。 癌細胞死亡方式包含兩大模式:細胞壞死(necr〇sis )以及細胞凋亡(apoptosis)。 『細胞壞死』是因外力或外在環境造成的創傷,如局 部缺血、缺氧或係補體攻擊、外來毒素等等所引起的細胞 死亡’此種機轉常同時伴隨有發炎反應,並造成組織中多 種細胞同時被殺死。(Van Cruchten, S. and Van Den, B.W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 2002, 31, 214-223) 『細胞凋亡』同時也被稱作為『細胞計畫性死亡』 (programmed ce 11 death),係因為 DNA損害而無法被修 201008572 .復,致使細胞走向死亡的過程(Lowe,S.W. and Lin,A.W. Apoptosis in cancer. Carcinogenesis. 2000, 21, 485-495. ; FiT chenkov, A. A. Apoptosis modulators. Biomed. Khim. 2003,49,333-359),同時也是生物體内 部正常組織在發育時,必然的一種汰舊換新過程;在活體 .(in vivo)内,細胞凋亡常扮演著維持細胞數目恆定 (homeostasis)的重要角色,許多研究結果顯示,細胞凋 亡路徑之缺損是導致癌症發生的一個重要因素之一 © (Tsujimoto, Y. , Cossman, J. , Jaffe, E. and Croce, C.M. Involvement of the be 1-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443; * Hengartner M. 0. The biochemistry of apoptosis comment. Nature 2000, 407, 770-776) 〇 目前臨床上所使用之抗癌藥物,有許多是針對細胞凋 亡路徑產生誘導作用,進而達到抗癌之作用(Tolcher A. W. Regulators of apoptosis as ant i cancer targets. Hematol. Oncol. Clin. North Am. 2002, 16, 1255- 1 267; Ferreira, C.G., Epping, M. , Kruyt, F.A., et -a 1. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002;8:2024 -2034);因此,如何有效引 導癌細胞進入細胞凋亡路徑,是抗癌藥物重要的分子機轉 之一 〇 『香茹』(Glossogyne tenuifolia)又名『風祐』, 別名『山參仔』、『南香茹』 『鐵釣竿』 『金鎖匙』 6 201008572 .等’屬菊科、多年生宿根性草 利濕消腫、活血化瘀、治感冒 、肺熱發炎、急性扁桃腺炎、 功效。 本植物,具有解熱、解毒、 發熱、腹熱痢疾、渥熱浮腫 支氣管炎、尿道炎及保肝等 國内外已有針對香兹 曾由香茹草中分析出 草的相關研究報告:林哲輝等人 oleanolic acid 、 luteolin 、201008572 . IX. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a medicinal herb, a remedy for a lung cancer, and a method for preparing the same, and more particularly, It is derived from the anti-lung cancer bio-aerobic substance in Glossogyne tenui folia, which can be used to inhibit or prevent lung cancer by solvent extraction, column chromatography and high-efficiency column chromatography. Cell growth. [Prior Art] ©#CANCER is a cancer with low cure rate and recurrence after cure. The treatment methods include: surgical therapy, radiation therapy and chemotherapy, among which chemotherapy is still i, supplemented with hands Mixed application of # and radiation therapy to prevent metastasis and recurrence of cancer to improve long-term survival. Therefore, the development of 'new anti-lung cancer compounds will help improve the effectiveness of chemotherapy. Cancer cell death patterns include two major modes: cell necrosis (necr〇sis) and apoptosis (apoptosis). "Cell necrosis" is a trauma caused by external or external environment, such as ischemia caused by ischemia, hypoxia or complement attack, foreign toxins, etc. 'This machine is often accompanied by an inflammatory reaction and causes Multiple cells in the tissue are killed at the same time. (Van Cruchten, S. and Van Den, BW Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 2002, 31, 214-223) "Apoptosis" is also known as the "Cell Project" "Scheduled death" (programmed ce 11 death), due to DNA damage, can not be repaired 201008572. The process of causing cells to die (Lowe, SW and Lin, AW Apoptosis in cancer. Carcinogenesis. 2000, 21, 485-495. FiT chenkov, AA Apoptosis modulators. Biomed. Khim. 2003, 49, 333-359), and also an inevitable replacement process for normal tissues inside the organism; in vivo, Apoptosis often plays an important role in maintaining a constant number of homeostasis. Many studies have shown that a defect in the apoptotic pathway is one of the important factors leading to cancer occurrence (Tsujimoto, Y., Cossman, J., Jaffe, E. and Croce, CM Involvement of the be 1-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443; * Hengartner M. 0. The biochemistry o Nature: toxic cytokines I cancer targets. Hematol. Oncol. Clin. North Am. 2002, 16, 1255- 1 267; Ferreira, CG, Epping, M., Kruyt, FA, et-a 1. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002;8:2024 -2034); Therefore, how to effectively guide cancer cells into the apoptotic pathway is one of the important molecular mechanisms of anticancer drugs. Glossogyne tenuifolia is also known as "wind blessing" , Alias "Shansongzi", "South Xiangru" "Iron fishing rod" "Golden key" 6 201008572 . Waiting for 'a genus Compositae, perennial perennial grass, dampness, swelling, promoting blood circulation, treating colds, lung heat, Acute tonsillitis, efficacy. The plant has antipyretic, detoxification, fever, abdominal heat dysentery, hot edema bronchitis, urethritis and liver protection, and other domestic and foreign research reports on the analysis of grass by Xiangzi in the fragrant grass: Lin Zhehui et al. Acid, luteolin,

1114〇1111-711此0以心及1[(:1等化學成份(林哲輝、周正 仁、劉國桂:香茹之成份研究.台灣地區中醫文獻摘要第 一輯’ 193 (1975));林榮貴的研究證實,香茹草之萃取 物可治療化學性傷害之肝炎(林榮貴:澎湖縣藥用植物資 源之調查研究.中國醫藥學院藥學系碩士論文(1997)); 蔡佳宏之研究結果則顯示,香茹草萃取物對Salm〇neHa • typhimurium T1 535 NQN0直接導致突變劑誘發的突變效應 具有明顯的抑制作用(蔡佳宏:十種台灣本產務抗致突變 性之研究·國立屏東科技大學食品科學系碩士論文 (2000))。在Wu等人的研究報導,由香茹草中分離所得之 ❹ 成份有 oleanolic acid ' luteolin ' luteolin-7-glucoside 、 β -sitosterol ' stigmasterol 、 stearic -acid及palmitic acid等’並針對香茹之抗發炎及抗B型肝 炎表面抗原表現功能進行研究,發現香茹草可以抑制B型 肝炎表面抗原表現(Wu MJ, Wang L, Ding HY,Weng CY and Yen JH. ( 2004 ) G1ossogyne tenu i folia acts to inhibit inflammatory mediator production in a macrophage cell line by downregulating LPS- 7 201008572 induced NF-kappa B. J. Biomed. Sci. 11(2): 186-199) ;同時,香茹草之粗萃物係具有很強的抗氧化能力 (Wll MJ, Huang CL, Lian TW, Kou MC and Wang L. (2005a). Anti oxidant activity of G1 ossogyne tenui folia. J. Agric. Food Chem. 53, 6305-6312 ; Hsu HF, Houng JY,1114〇1111-711 This 0 is the heart and 1[(:1 and other chemical components (Lin Zhehui, Zhou Zhengren, Liu Guogui: Research on the ingredients of Xiangru. The first series of TCM literature abstracts in Taiwan] 193 (1975)); Lin Ronggui's research It is confirmed that the extract of fragrant grass can treat hepatitis with chemical injury (Lin Ronggui: Investigation and study of medicinal plant resources in Wuhu County. Master's thesis of Pharmacy Department of China Medical College (1997)); Cai Jiahong's research results show that fragrant grass The extract has a significant inhibitory effect on the mutation-induced mutation effect of Salm〇neHa • typhimurium T1 535 NQN0 (Cai Jiahong: Ten kinds of Taiwan's anti-mutagenic research) · Master's thesis, Department of Food Science, National Pingtung University of Science and Technology (2000)). According to a study by Wu et al., the ingredients obtained from the separation of fragrant grass are oleanolic acid ' luteolin ' luteolin-7-glucoside , β -sitosterol ' stigmasterol , stearic - acid and palmitic acid , etc . The anti-inflammatory and anti-hepatitis B surface antigen function of Xiangru was studied, and it was found that the fragrant grass can inhibit the surface antigen expression of hepatitis B (Wu MJ, Wan g L, Ding HY, Weng CY and Yen JH. ( 2004 ) G1ossogyne tenu i folia acts to inhibit inflammatory mediator production in a macrophage cell line by downregulating LPS-7 201008572 induced NF-kappa BJ Biomed. Sci. 11(2): 186-199) ; At the same time, the crude extract of the fragrant grass has strong antioxidant capacity (Wll MJ, Huang CL, Lian TW, Kou MC and Wang L. (2005a). Anti oxidant activity of G1 ossogyne tenui folia J. Agric. Food Chem. 53, 6305-6312 ; Hsu HF, Houng JY,

Chang CL, Wu CC, Chang FR and Wu YC. (2005)Chang CL, Wu CC, Chang FR and Wu YC. (2005)

Antioxidant Activity, Cytotoxicity and DNA Information of G1ossogyne teniufolia. J. Agric. Food Chem., 53: 6117-6125 ; Yang, J.H., Tsai, S.Y., Han, C.M., Shih, C. C. , Mau, J. L., 2006.Antioxidant Activity, Cytotoxicity and DNA Information of G1ossogyne teniufolia. J. Agric. Food Chem., 53: 6117-6125; Yang, J.H., Tsai, S.Y., Han, C.M., Shih, C. C., Mau, J. L., 2006.

Antioxidant properties of Glossogyne tenuifolia. 'Am. J. Chin. Med. 34, 707-720);此外,香茹乙醇萃取 物具有抗發炎效果,其係藉由調控i NOS的轉錄來抑制一氧 化氮合成酶的表達,進而抑制一氧化氮的生合成,其中 〇16311〇14 3(^(1及1111:6〇1111-7-莒11^03 1(16為香茹抗發炎之 指標成份(Wu MJ,Weng CY,Ding HY and Wu PJ ( 2005b)Antioxidant properties of Glossogyne tenuifolia. 'Am. J. Chin. Med. 34, 707-720); in addition, the ethanol extract of fragrant ruthenium has an anti-inflammatory effect by inhibiting the transcription of i NOS to inhibit nitric oxide synthase The expression, in turn, inhibits the biosynthesis of nitric oxide, which is 〇16311〇14 3(^(1 and 1111:6〇1111-7-莒11^03 1 (16 is the indicator component of Xiangru anti-inflammatory (Wu MJ, Weng CY, Ding HY and Wu PJ (2005b)

Anti-inflammatory and antiviral effects of Glossogyne tenuifolia. Life Sci. 76(10): 1135-1146) •;再者,香茹草中之黃酮類物質Luteolin及11^6〇1丨11-7-glucoside亦已被證實具有抗氧化以及對於MDA —MB_231、 MCF-7 (乳癌)、Hep G2、Hep 3B (肝癌)及 A549 (肺癌)等 癌細胞系具有毒殺效力,其中尤以對Hep G2肝癌細胞之 毒殺效用最為顯著(Hsu HF,Houng JY,Chang CL, Wu CC, Chang FR and Wu YC. (2005) Antioxidant 8 201008572 •Activity, Cytotoxicity and DNA Information ofAnti-inflammatory and antiviral effects of Glossogyne tenuifolia. Life Sci. 76(10): 1135-1146) • In addition, the flavonoids Luteolin and 11^6〇1丨11-7-glucoside in the fragrant grass are also It has been shown to have antioxidant effects and is toxic to cancer cell lines such as MDA-MB_231, MCF-7 (breast cancer), Hep G2, Hep 3B (liver cancer) and A549 (lung cancer), especially for Hep G2 liver cancer cells. Most notable (Hsu HF, Houng JY, Chang CL, Wu CC, Chang FR and Wu YC. (2005) Antioxidant 8 201008572 • Activity, Cytotoxicity and DNA Information of

Glossogyne teniufolia. J. Agric. Food Chem., 53: 6117-6125)。 本案發明人致力於相關領域之研究與開發多年,對於 相關技術擁有相當程度瞭解,有鑒於先前研究雖已證實香 .4草中之物質對肝癌、肺癌等癌細胞具有毒殺效力,但其 .作用機轉並未曾被探討及具體實施,是以發明人本著精益 求精之精神潛心研究,歷經數年的尋思探索並經過多次嚴 ©密測試與討論,終於完成本發明。 【發明内容】 本發明之主要目的,在於揭示Dehydr〇c〇stus .與Glossogin等兩種源自於香茹草中具有抑制肺癌細胞生 .長之生物活性物質、以及製備此兩種物質之方法,同時並 提供本發明所揭示抗肺癌物質之應用方法。 依據上述目的,本發明所述之香茹草抗肺癌物質及其 ❹製備方法即係為符合產業應用上之需要,從而建立香茹草 抗肺癌物質之分離純化方法’並經審慎探討其操作條件 •終而獲致可供工業化規模生產之製造程序,装 六王要包含: ' (1 )將香茹草利用水或有機溶劑萃取,得到卷—社 ^货如草細莖 (2) 租平初利用装 J用再他不同有機 將步驟(1 )所得之香 溶劑進行萃取分層,以得到香茹草精萃物· 將步驟(2)所得香茹草精萃物使用碎膠总 ^ B 層才斤 行分離,以得到香茹草有效區分物; 9 (3) 201008572 .(4)使用製備型高效液相層析管柱以針對步驟所得 香茹草有效區分物進行分離純化,俾得到本發明所 揭示之三種抗肺癌活性化合物。 關於香茹草抗肺癌生物活性物質之應用方法, 包含: 要係 .(1)使用含本發明所揭示香茹草抗肺癌物質的粗萃物, 作為人體預防肺癌細胞產生之應用; (2) 使用含本發明所揭示香茹草抗肺癌物質的精萃物, 〇 作為人體預防肺癌細胞產生之應用; (3) 使用含本發明所揭示香茹草抗肺癌物質的有效區分 物’作為人體預防肺癌細胞產生之應用; * (4)使用本發明所揭示方法製得各種純物質,作為人體 預防肺癌細胞產生之應用; (5) 使用含本發明所揭示香茹草抗肺癌物質的粗萃物, 作為抑制人體肺癌細胞生長之應用; (6) 使用含本發明所揭示香兹草抗肺癌物質的精萃物, ® 作為抑制人體肺癌細胞生長之應用; .(7)使用含本發明所揭示香茹草抗肺癌物質的有效區分 - 物’作為抑制人體肺癌細胞生長之應用; (8)使用本發明所揭示方法製得各純物質作為抑制人 體肺癌細胞生長之應用。 為期許對於本發明之目的、功效及構造特徵能有 細月確的瞭解,兹舉出如下述較佳之實施例並配合圖式說 201008572 .【實施方式】 本發明所述之香茹草抗肺癌物質及其製備方法,主要 係在揭示由香茹中分離純化出Dehydrocostus lactone與 G1 ossogi η等兩種物質及其分離方法,並揭示此等抗肺癌 物質之應用方法’證明此兩種物質能抑制肺癌細胞之生長 .;請參閱第一圖’其列示該物質之化學結構,並揭示該物 質之化學式如下: (1) Dehydrocostus lactone : 6-Hydroxy-guaia- © 4(15),10(14),lK13)-trien-12-oic acid lactone.如第 一圖(A)。 (2 ) Glossogin · 1 -Acetoxy-4-〇-isova1yry1eugeno1. ' 如第一圖(B)。 • 關於本說明書内容之用語「MTT 分析法」,係指在 1 9 8 0年代由美國國家癌症研究所癌症治療部門之發展性治 療計畫所建構的一個抗癌藥劑篩選流程(A1 ley M. C. et ▲ a 1. , Feasibility of drug screening with panels of ❹ human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589-601, 1988; * Scud i ero D. A. et a 1. , Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48: 4827-4833, 1988;Glossogyne teniufolia. J. Agric. Food Chem., 53: 6117-6125). The inventor of this case has been committed to the research and development of related fields for many years, and has a considerable understanding of related technologies. In view of the previous research, it has been confirmed that the substances in Xiang.4 grass have poisoning effect on cancer cells such as liver cancer and lung cancer, but their effects The machine has not been discussed and implemented in detail. It is the inventor's research in the spirit of excellence. After several years of thinking and exploration, and after many times of close testing and discussion, the present invention has finally been completed. SUMMARY OF THE INVENTION The main object of the present invention is to disclose Dehydr〇c〇stus and Glossogin, two biologically active substances derived from the scented grass which inhibit the growth of lung cancer cells, and a method for preparing the same At the same time, the application method of the anti-lung cancer substance disclosed by the present invention is provided. According to the above object, the method for preparing the anti-lung cancer substance and the cockroach of the genus of the genus of the present invention is in accordance with the needs of industrial application, thereby establishing a method for separating and purifying the lung cancer-resistant substance of the fragrant grass, and carefully discussing the operating conditions thereof. • In the end, the manufacturing process for industrial scale production will be included, and the six kings will include: ' (1) Extracting the fragrant grass with water or organic solvent to obtain a volume--a service such as a grass stem (2) The fragrant solvent obtained in the step (1) is extracted and layered by using different materials to obtain the extract of the fragrant grass extract. The extract of the fragrant grass obtained in the step (2) is used as the total layer B of the crushed rubber. Separate to obtain an effective distinction of the fragrant grass; 9 (3) 201008572 . (4) Separate and purify the effective fraction of the fragrant grass obtained by the preparative high-performance liquid chromatography column. The three anti-lung cancer active compounds disclosed in the invention. The method for applying the anti-lung cancer biological active substance of the fragrant grass comprises: (1) using a crude extract containing the anti-lung cancer substance disclosed by the present invention as a human body for preventing the production of lung cancer cells; (2) The use of the extract containing the anti-lung cancer substance of the scented grass of the present invention, the use of hydrazine as a human body to prevent the production of lung cancer cells; (3) the use of an effective distinguishing substance containing the anti-lung cancer substance of the fragrant grass disclosed in the present invention as a human prevention Application of lung cancer cell production; * (4) using the method disclosed in the present invention to prepare various pure substances as a human body for preventing the production of lung cancer cells; (5) using a crude extract containing the lung cancer-resistant substance of the fragrant grass disclosed in the present invention As an application for inhibiting the growth of human lung cancer cells; (6) using an extract containing the anti-lung cancer substance disclosed by the present invention, ® as an application for inhibiting the growth of human lung cancer cells; (7) using the present invention The effective differentiation of the scented grass against lung cancer substances - the use of 'skin' as a method for inhibiting the growth of human lung cancer cells; (8) using the method disclosed in the present invention to obtain various pure substances as a human body Application of the growth of cancer cells. In order to have a clear understanding of the purpose, efficacy and structural features of the present invention, the following preferred embodiments are described in conjunction with the drawings. 201008572. [Embodiment] The fragrant grass of the present invention is resistant to lung cancer. The substance and its preparation method mainly reveal the separation and purification of Dehydrocostus lactone and G1 ossogi η from the fragrant ruthenium and the separation methods thereof, and reveal the application methods of these anti-lung cancer substances to prove that the two substances can inhibit lung cancer Cell growth; see the first figure 'which lists the chemical structure of the substance and reveals the chemical formula of the substance as follows: (1) Dehydrocostus lactone : 6-Hydroxy-guaia- © 4(15),10(14) , lK13)-trien-12-oic acid lactone. As shown in the first figure (A). (2) Glossogin · 1 -Acetoxy-4-〇-isova1yry1eugeno1. ' As shown in the first figure (B). • The term “MTT analysis” as used in this manual refers to an anticancer drug screening process constructed by the National Cancer Institute's Cancer Treatment Department's Developmental Therapy Program in the 1980s (A1 ley MC et ▲ a 1. , Feasibility of drug screening with panels of ❹ human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589-601, 1988; * Scud i ero DA et a 1. , Evaluation of a soluble tetrazolium/ Formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48: 4827-4833, 1988;

Vi st i ca D. T. et a 1., Tetrazo1ium-based assays for cellular viability: a critical examination of 201008572 selected parameters affecting formazan. Cancer Res. 51: 2515-2520, 1991; Monks A. et al., Feasibility of a high-flux anti cancer drug screen using a diverse panel of cultured human tumor cell lines. J. Nat. Cancer Inst. 83: 757-766, 1991)。在此分析 方法中,具有抗癌效果之物質(在本發明中即為源自於香 茹草分離所得之抗癌物質)被測試其對抑制肺癌細胞株生 長之能力。其分析原理為 3-[4,5-dimethylthiazol-2-❹ yl]-2,5-diphenyltetrazolium bromide (簡稱MTT)黃色 水溶性固體可被細胞内粒腺體(mi tochondr i a)中的去氫酵 素(dehydrogenase)代謝,將四唑環(tetrazolium ring) ‘ 切斷還原呈紫色不溶性沈殿物甲臢(f o r m a z a η)。因為活細 • 胞的粒線體酵素才具有活性,所測得的吸光值會與活細胞 數量成正比關係,因此可利用甲臢產量的多寡來評估細胞 的存活率。 關於本說明書内容之用語「1C”值」,係指在施用抗 癌物質時,能導致百分之五十.肺癌細胞死亡之劑量。當 ▲ IC5。值愈低時,表示該抗癌樣品在較低劑量下,即可使百 -分之五十癌細胞死亡,亦表示其抑制癌細胞生長之能力愈 佳。 以下即針對本發明各實施例詳述如後: 實施例一、香茹草管柱層析有效區分產物抑制肺癌細胞生 長之效果: 將全株香茹草以細碎機打成粉末,取5. 3公斤放入2〇 12 201008572 .公升9 5 %乙醇浸泡一天,以紗布過據後 再分別使用9 π 升95%乙醇萃取三次。經過濾後,收隹, &用公 1人茱乙醇萃取液 _ 壓濃縮以去除乙醇溶液,經冷凍乾燥I 進行減 ”艰:/東乾樣品 樣品共776. 67公克。取400公克凍乾姆 仔乾燥 诹品再溶於丨5公 95%乙醇溶液中,加入1.5公升乙酸乙和_ 升 3進行分層,經播拉 混合均勻,靜置待溶液分層後收集乙酿7 ^ Ψ .、 乙酯層,此步驟重 複5次,將5次所得之乙酸乙醋層液體淮〜 • 仃减壓濃縮及冷凌 乾燥,可得71. 9公克產物,此一產物合交 ρ名為「香茹草乙酸 ©乙醋萃取物」。 取61 ·5公充乾综的杳蘇軍乙酸乙酯萃取物,玫入填充 2. 5公斤Si-60矽膠(40-63 μπι,Merck Co.)之層析管柱(内 徑120 mm’管長760 mm)内’流動相為正己烷和乙酸乙醋 ’其比例由90: 10、80-20,逐漸增加至1〇〇%乙酸乙醋最 後以1 0 0 %甲醇沖洗,每一比例之流動相皆使用1. 5公升。Vi st i ca DT et a 1., Tetrazo1ium-based assays for cellular viability: a critical examination of 201008572 selected parameters affecting formazan. Cancer Res. 51: 2515-2520, 1991; Monks A. et al., Feasibility of a high -flux anti cancer drug screen using a diverse panel of cultured human tumor cell lines. J. Nat. Cancer Inst. 83: 757-766, 1991). In this analysis method, a substance having an anticancer effect (in the present invention, an anticancer substance derived from the separation of fragrant grass) is tested for its ability to inhibit the growth of a lung cancer cell line. The analytical principle is 3-[4,5-dimethylthiazol-2-❹yl]-2,5-diphenyltetrazolium bromide (MTT). The yellow water-soluble solid can be dehydrogenase in the intracellular granule (mi tochondr ia). (dehydrogenase) metabolism, the tetrazolium ring 'tetrazolium ring' is cut and reduced to purple insoluble sputum foraza (formaza η). Because the mitochondrial enzyme is active, the measured absorbance is directly proportional to the number of viable cells, so the amount of hyperthyroidism can be used to assess cell viability. The term "1C" value in the context of the present specification means a dose which causes 50% of lung cancer cells to die when an anticancer substance is administered. When ▲ IC5. The lower the value, the lower the dose of the anticancer sample, and the death of 50% of the cancer cells, which means that the ability to inhibit the growth of cancer cells is better. The following is a detailed description of various embodiments of the present invention as follows: Example 1, the scented column chromatography effectively distinguishes the effect of the product on inhibiting the growth of lung cancer cells: The whole plant fragrant grass is powdered into a powder by a fine crusher. 3 kg was placed in 2〇12 201008572. The liter was immersed in 95% ethanol for one day, and the gauze was passed through and then extracted with 9 π liters of 95% ethanol three times. After filtration, the sputum, & used a public 茱 ethanol extract _ pressure concentrated to remove the ethanol solution, lyophilized I to reduce the "hard: / East dry sample sample a total of 776. 67 grams. Take 400 grams of lyophilized The dried product was dissolved in 丨5 male 95% ethanol solution, and 1.5 liters of acetic acid B and _ liter 3 were added for stratification, which was evenly mixed by sowing. After standing to dissolve the solution, the mixture was collected and 7 ^ Ψ was collected. , the ethyl ester layer, this step is repeated 5 times, 5 times of the obtained ethyl acetate layer liquid Hua ~ ~ 仃 decompression concentrated and cold drying, can get 71. 9 grams of product, this product meets the ρ name Fragrant acetic acid acetic acid extract. Take the ethyl acetate extract of 61 军 军 61 61 61 61 61 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 The tube length is 760 mm), the mobile phase is n-hexane and ethyl acetate. The ratio is gradually increased from 90: 10, 80-20 to 1% acetic acid ethyl acetate and finally washed with 100% methanol. 5升升。 The mobile phase is used 1. 5 liters.

另一方面,使用分液收集器收集流出此層析管柱之液體, 並於固定時間換一支收集管。在此管柱分離操作進行當中 ’使用薄膜色層分離鋁片(MERCK Co.)以不同比例之正己 烷和乙酸乙酯展開液及乙酸乙酯和甲醇展開液作為移動相 ,各收集管内樣品組成成分依展開液極性大小展開在不同 位置上,並以254 nm和365nm紫外線燈光下判斷色斑的位 置和大小以進行定性分析。同時,將含有Mokko lactone 、Dehydrocostus lactone與 Glossogin等三種物質之收集 管内樣品合併,經減壓濃縮及冷凍乾燥後’可得1. 〇 5 5公 克產物,此一產物命名為「香兹草有效區分物 13 201008572 (effeetive fraction)」。其中 ’ Mokko lactone 、 dehydrocostus lactone 與 glossogin等二種物質分別含有 25. 24%、11.05% 和18.56%。 將A549肺癌細胞系培養於含有10% fetal bovine serum、1 % penici11in/streptomycin 與 1.5 g/1 sodium bicarbonate 的 Dulbecco’ s modified Eagle’ s medium (DMEM-F12)培養基中,置於37°C、5% C〇2的培養箱中培養 。取3 xl03個A549細胞培養於96孔培養盤,每孔加入含有 ©不同濃度的香茹草乙酸乙酯萃取物或香茹草有效區分物, 以及 10% fetal bovine serum 、 1 % penicillin /streptomycin 與 1.5g/l sodium bicarbonate 的 DMEM- 'F12培養基,置於37°C、5% C(h的培養箱中培養。經培 - 養7 2小時後,將原培養液移除,再加入丨〇 〇 μ丨含有丄 mg/ml MTT的DMEM-F12培養基培養1小時,將培養液移除, 再加入 ΙΟΟμΙ 二甲亞砜(dimethyl sulfoxide,簡稱 DMS0) ❹攪拌至沉澱物溶解,以免疫分析儀(ELISA reader)於 550nm波長下測定吸光值。 由MTT分析結果顯示’香茹草乙酸乙酯萃取物對於 .A549肺癌細胞之抑制生長效果不顯著,而香茹草有效區 分物對抑制A549細胞生長之效果則極佳(如第二圖所示) 其 IC5。值達到 18. 23 pg/ml。 實施例一、香祐草管柱層析香莊草漢縮區分產物抑制肺癌 細胞生長之效果: 取0.95 5公克乾燥的香兹草有效區分物放入填充15〇 14 201008572 .公克Si-60石夕膠(40-63 μΐη,Merck Co.)之層析管柱(内徑 45 mm ’管長60 0 mm)内,流動相為正己烷和乙酸乙酯, 其比例由90:10、80-20,逐漸增加至乙酸乙酯,每一 比例之流動相皆使用2 0 0毫升。另一方面,使用分液收集 器收集流出此層析管柱之液體,並於固定時間換一支收集 .管。在此管柱分離操作進行當中,使用薄膜色層法分析各 收集管内樣品組成成分,並將含有Mokko iactone、 Dehydrocost us lac tone與Glossogi η等三種物質之收集管 ©内樣品合併’經減壓濃縮及冷凍乾燥後,可得46. 5毫克產 物,此一產物命名為「香茹草濃縮區分物」。其中, Dehydrocostus lactone與Glossogin等兩種物質分別含有 ' 33. 03% 和 16.45%。 依實施例二之MTT抑制肺癌細胞生長測試結果顯示, 此香茹草濃縮區分物對於A549肺癌細胞之抑制生長效果較 香茹草有效區分物為佳(如第三圖所 罔^不)’其IC5。值達到 ❹ 11.56pg/ml 。 實施例二、香兹草抗癌成分對抑制肺访^ + > 屬細胞生長之效果: 將約44毫克香茹草濃縮區分物以彻 ^ y 2 ^ ^ . 製備型高效液相層析 儀進行抗癌成分之純化,所使用之展 * 巧析管柱為STAR Si管 柱(RT-250, Hibar Fertigsaule, 5 认班,1〇 _ χ 250 mm) ’流動相為正己烷和乙酸乙酯,Α μ 、多或,^比例為90:10,體積流 迷為 1 m 1 /m 1 η。 7毫克黃色油狀之 (6-hydroxy-guaia- 透過此一純化操作,可到得l4 dehydrocostus lactone : 15 201008572 4(15), 10(14), ll(13)-trien-12-oic acid 1 actone): [a]28.2 = -16.67°; IR (CHC13) vmax 1764, 1639 cm-1; EIMS: m/z 231 (M+H)+, 1H NMR (400 MHz) δ 1.42 (1H, dddd, J = 13.2, 11. 5, 10.2, 5.6 Hz, H-8), 1.87 (1H, ddd, J = 13.2, 4 .7, 2. 7 Hz, H-2), 1.95 (1H, ddd, J =13. 2, 7.6, 1. 7 Hz, H-2), 2. 16 (1H, dddd, J = 12.2, 10 .4,5.6, 5. 6 Hz, H-9), 2.24 (1H, dddd, J = 13.2, 8. 2, 5. 8, 4. 4 Hz, H-8), 2.87 (1H, dd, J = 9.3, 3. C 1 Hz, H- 5), 2.82-2.95 (2H, m, H-l, H-7), 3. 97 (1H, t, J = 18.4 Hz, H-6), 4.81 (1H, s, H- 15a), 4. 90 (1H, s, H-15b), 5.06 (1H, br d, J = 2.0On the other hand, a liquid separator is used to collect the liquid flowing out of the chromatography column, and a collection tube is exchanged at a fixed time. During the column separation operation, 'using a thin film chromatography aluminum sheet (MERCK Co.) with different ratios of n-hexane and ethyl acetate developing solution and ethyl acetate and methanol developing solution as the mobile phase, the sample composition in each collecting tube The composition was developed at different positions according to the polarity of the developing liquid, and the position and size of the stain were judged by ultraviolet light at 254 nm and 365 nm for qualitative analysis. At the same time, a sample of the collection tube containing three substances, such as Mokko lactone, Dehydrocostus lactone and Glossogin, was combined, and after concentration under reduced pressure and freeze-dried, a product of 1. 5 5 g was obtained, and the product was named as "Zhezi Grass effectively differentiated. Matter 13 201008572 (effeetive fraction)". Among them, 'Mokko lactone, dehydrocostus lactone and glossogin contain 25.24%, 11.05% and 18.56%, respectively. The A549 lung cancer cell line was cultured in Dulbecco's modified Eagle's medium (DMEM-F12) medium containing 10% fetal bovine serum, 1% penici11in/streptomycin and 1.5 g/1 sodium bicarbonate, and placed at 37 ° C, 5 Incubate in an incubator of % C〇2. 3 xl03 A549 cells were cultured in 96-well culture plates, and each well was added with different concentrations of eucalyptus ethyl acetate extract or fragrant grass virgin, and 10% fetal bovine serum, 1% penicillin /streptomycin and 1.5 g/l sodium bicarbonate in DMEM- 'F12 medium, cultured at 37 ° C, 5% C (h in an incubator. After cultured for 7 hours, remove the original culture solution and add 丨〇 〇μ丨DMEM-F12 medium containing 丄mg/ml MTT was incubated for 1 hour, the culture solution was removed, and then dimethyl sulfoxide (DMMS0) was added and stirred until the precipitate was dissolved to obtain an immunoassay analyzer ( ELISA reader) The absorbance was measured at 550 nm. The results of MTT analysis showed that the ethyl acetate extract of 'Rhodoside' had no significant effect on the growth inhibition of A549 lung cancer cells, while the effective differentiation of the fragrant grasses inhibited the growth of A549 cells. The effect is excellent (as shown in the second figure), its IC5 value reaches 18.23 pg/ml. Example 1, Xiangyou grass column chromatography, Xiangzhuang grass Han contraction differentiation product inhibits the growth of lung cancer cells: 0.95 5 grams dry The effective distinction of the fragrant grass is placed in a packed column of 15〇14 201008572. gram Si-60 Shiyuejiao (40-63 μΐη, Merck Co.) in a chromatography column (inner diameter 45 mm 'tube length 60 0 mm), flowing The phases were n-hexane and ethyl acetate, the ratio was gradually increased from 90:10, 80-20 to ethyl acetate, and the mobile phase was used for each ratio of 200 ml. On the other hand, the liquid collection collector was used for collection. The liquid flowing out of the column is replaced by a collection tube at a fixed time. During the column separation operation, the sample composition in each collection tube is analyzed by a film chromatography method and will contain Mokko iactone, Dehydrocost us. The collection of three substances, such as lac tone and Glossogi η, is combined with the sample. After concentration under reduced pressure and lyophilization, 46.5 mg of the product is obtained. This product is named "Fruit Grass Concentrate". Among them, Dehydrocostus The two substances, lactone and Glossogin, contained '33.03% and 16.45%, respectively. According to the results of MTT inhibition of lung cancer cell growth test in Example 2, the concentration of this fragrant grass stalk was inhibited by A549 lung cancer cells. The effective distinguishing substance is better (as shown in the third figure), its IC5 value reaches ❹ 11.56pg/ml. Example 2, the anti-cancer component of zizi grass inhibits lung access ^ + > : Approximately 44 mg of fragrant grass concentrated fractions were purified by preparative high-performance liquid chromatography to prepare anti-cancer components. The column used for the analysis was a STAR Si column (RT). -250, Hibar Fertigsaule, 5 Class, 1〇_ χ 250 mm) 'The mobile phase is n-hexane and ethyl acetate, Α μ, more or, ^ ratio is 90:10, volume flow is 1 m 1 /m 1 η. 7 mg of yellow oil (6-hydroxy-guaia- through this purification operation, can be obtained l4 dehydrocostus lactone: 15 201008572 4 (15), 10 (14), ll (13)-trien-12-oic acid 1 Actone): [a]28.2 = -16.67°; IR (CHC13) vmax 1764, 1639 cm-1; EIMS: m/z 231 (M+H)+, 1H NMR (400 MHz) δ 1.42 (1H, dddd, J = 13.2, 11. 5, 10.2, 5.6 Hz, H-8), 1.87 (1H, ddd, J = 13.2, 4 .7, 2. 7 Hz, H-2), 1.95 (1H, ddd, J = 13. 2, 7.6, 1. 7 Hz, H-2), 2. 16 (1H, dddd, J = 12.2, 10 .4, 5.6, 5. 6 Hz, H-9), 2.24 (1H, dddd, J = 13.2, 8. 2, 5. 8, 4. 4 Hz, H-8), 2.87 (1H, dd, J = 9.3, 3. C 1 Hz, H- 5), 2.82-2.95 (2H, m , Hl, H-7), 3. 97 (1H, t, J = 18.4 Hz, H-6), 4.81 (1H, s, H- 15a), 4. 90 (1H, s, H-15b), 5.06 (1H, br d, J = 2.0

Hz, H-14a), 5.27 (1H, br d, J = 2.0 Hz, H-14b), 5.49 (1H, d, J = 3.2 Hz, H-12a), 6.22 (1H, d, J = 3.6 Hz, H-12b); 13C NMR (100 MHz) δ 30.28 (C-2), 30.91 (C-8), 32.57 (C-3), 36.25 (C-9), 45.10 (C-7), 47.58 (C-l), 52.01 (C-5), 85.23 (C-6), 109.60 (C- f 14), 112.61 (C-15), 120.19 (C-12), 139.71 (C-ll), •149.21 (C-10), 151.22 (04), 1 70.24 (C-13); -mo 1 ecu 1ar: C15H1 802. 同時亦能得到7 . 3 4毫克黃色油狀之£1〇880£丨11(1’-acetoxy-4-O-isovalyryleugenol): [α] 2 7.6 = -34.5。 (CHC13); IR (CHC13) vmax 1743, 1587 cm-1; EIMS: m/z 305.8 (M-H)+, 1H NMR (400 MHz) δ 1.06 (6H, d, J =6_8 Hz, H-4” , H-5” ), 2.11 (3H, s, H-5’ ), 2_25 16 201008572 (1H,m,H-3”),2.45 (2H,d,J = 7·2 Hz’ H-2”), 3.82(3H,s,H_7),5.26(lH,d,J = i〇.4Hz,H-3’ a), 5.31 (1H,d, J = 17.2 Hz, H-3,b),5 99 (1H ddd,J = 17.2,10.8,5.6 Hz, H-2’ ),6_25 (1H,d, J = 5.6 Hz,H-l’ ),6.94 (1H,dd,J = i2_4,2.0 Hz H-3), 6.941 (1H, t, J = 17.6 Hz, H-2), 6.99 (1H, d J = 8.4 Hz, H-6),13C NMR (100 MHz) δ 21.24 (C-5,) 22.33 (C-4’ ’,C-5”),25.90 (C-3”),43 〇4 (c_ H 2,),55.79 (C-7), 75.70 (C-l’),111.43 (C-2), 116.99 (C-3,),119.58 (C-3),122.79 (C-6),135.94 (C-2,),137.50 (C-l),139.59 (C-4),i511〇 (c_5), -1 69.90 (C-4’), 171.02 (C-l,,); molecular: • C17H2205. 第四圖為依實施例三之Μ T T抑制肺癌細胞生長測試结 果顯示,Dehydrocos tus lactone 與 Gloss〇gin 等兩種物質 對於A 5 4 9肺癌細胞之抑制效果皆極佳,估計其I c 5。值分別 ❹ 為 6. 27 和 48.49 pg/ml。 -實施例四、香茹草管柱層析有效區分產物抑制肺癌細胞生 - 長之作用: 將A549細胞以香茹草有效區分產物處理24-48小時, 使用磷酸緩衝液清洗後,放入75%乙醇於4°C放置過夜。隨 後,以磷酸緩衝液清洗兩次,再將細胞懸浮於含有40 pg/ml propidium iodide 及 0.1 mg/ml RNase A的磷酸緩 衝液,於37 °C處理30分鐘’最後以流式細胞儀(flow 17 201008572 • cytometer)來進行觀察。由第八圖所示,A549細胞在以 15草管柱層析有效區分產物處理後,一部份細胞之生長 期會停滞在sub-Gl期而不再生長與繁殖,因此香茹草有 區分產物會導致肺癌細胞循細胞凋亡路徑而死亡。而且 停滯在sub-Gl期之A549細胞數比率會隨著處理時間之增 .與施加的香茹草有效區分產物之劑量上升而增加(如第 圖所示)。 實施例五、香祐草有效成份Dehydrocostus lactone抑 ® 肺癌細胞生長之作用: 將 A549 細胞以 Dehydrocostus lactone 處理 24 至 48 時’再使用如實施例四所述之方法來觀察其對A549細胞 長週期之影響。如第九圖所示,A549細胞在 - Dehydrocostus lactone處理後,一部份細胞之生長週 會停滯在sub-Gl期而不再生長與繁殖,因此香茹草有效 分產物會導致肺癌細胞循細胞凋亡路徑而死亡。而且, 滯在sub-Gl期之A549細胞數比率亦會隨著處理時間之增 Ο 曰 與施加的香茹草有效區分產物之劑量上升而增加(如第 •圖所示)。 -實施例六、香茹草有效成份glossogin抑制肺癌細胞生 之作用: 將A549細胞以Glossogin處理24至48小時,再使用 實施例四所述之方法來觀察其對A 5 4 9細胞生長週期之影 。如第十圖所示’ A549細胞在以gl〇SSOgin處理後,一 份細胞之生長週期會停滯在sub-Gl期而不再生長與繁殖 香 週 效 長 五 制 小 生 以 期 區 停 長 六 長 如 響 部 18 标兮上述 201008572 •因此香知草有效區分產物會導致肺癌細胞循細胞凋 而死亡。而且,停滞在sub-Gl期之A549細胞數比率 著處理時間之增長與施加的香茹草有效區分產物之 升而增加(如第七圖所示)。 π〜Λ 丁丹另你ή 及實用性,同時查遍國内外關於此類技藝之技術^ 中,亦未發現有相同近似之構造存在於先,應已名 顆性』、『進步性』'『合於產業利用性』:及« ©』的專利要件’爰依法之提出申請。 唯,以上所述者僅係本發明之較佳實例而已, 應用本發明說明書及申請專利範圍所為 < 其他等交 -構變化者均屬可行,理應包含在本發明中請專利範 亡略裡 亦會隨 劑量上 之進步 料文獻 合『新 創作性 故舉凡 方法結 3内0 201008572 .【圖式簡單說明】 第一圖係列示 Dehydrocostus lactone與 Glossogin之化學 式。 第二圖係列示香茹草有效區分物對A549肺癌細胞生長之抑 制比率。 .第三圖係列示香茹草濃縮區分物對A549肺癌細胞生長之抑 制比率。 第四圖係列示香蘇草兩種抗癌化合物對A 5 4 9肺癌細胞生長 ®之抑制比率。 第五圖係列示以不同劑量香茹草管柱層析有效區分物處理 A549肺癌細胞經過24及48小時後停滞於sub-Gl期之細胞比 率 〇 第六圖係列示以不同劑量Dehydrocostus lactone處理 A549肺癌細胞,經過24及48小時後停滯於sub-Gl期之細胞 比率。 第七圖係列示以不同劑量G1 〇 s s 〇 g i η處理A 5 4 9肺癌細胞, 經過2 4及4 8小時後停滯於s u b - G1期之細胞比率。 •第八圖係列示A549細胞在以香茹草管柱層析有效區分產物 •處理之結果。 第九圖係列示A549細胞在以Dehydrocostus lactone處理 之結果。 第十圖係列示A549細胞在以Glossogin處理之結果。 【主要元件符號說明】 無 20Hz, H-14a), 5.27 (1H, br d, J = 2.0 Hz, H-14b), 5.49 (1H, d, J = 3.2 Hz, H-12a), 6.22 (1H, d, J = 3.6 Hz , H-12b); 13C NMR (100 MHz) δ 30.28 (C-2), 30.91 (C-8), 32.57 (C-3), 36.25 (C-9), 45.10 (C-7), 47.58 ( Cl), 52.01 (C-5), 85.23 (C-6), 109.60 (C-f 14), 112.61 (C-15), 120.19 (C-12), 139.71 (C-ll), •149.21 (C -10), 151.22 (04), 1 70.24 (C-13); -mo 1 ecu 1ar: C15H1 802. Also available is 7.3 mg of yellow oil in the form of £1〇880£丨11 (1'- acetoxy-4-O-isovalyryleugenol): [α] 2 7.6 = -34.5. (CHC13); IR (CHC13) vmax 1743, 1587 cm-1; EIMS: m/z 305.8 (MH)+, 1H NMR (400 MHz) δ 1.06 (6H, d, J = 6_8 Hz, H-4" , H-5"), 2.11 (3H, s, H-5'), 2_25 16 201008572 (1H, m, H-3"), 2.45 (2H, d, J = 7·2 Hz 'H-2") , 3.82(3H, s, H_7), 5.26(lH,d,J = i〇.4Hz, H-3' a), 5.31 (1H,d, J = 17.2 Hz, H-3,b),5 99 (1H ddd, J = 17.2, 10.8, 5.6 Hz, H-2'), 6_25 (1H, d, J = 5.6 Hz, H-l'), 6.94 (1H, dd, J = i2_4, 2.0 Hz H- 3), 6.941 (1H, t, J = 17.6 Hz, H-2), 6.99 (1H, d J = 8.4 Hz, H-6), 13C NMR (100 MHz) δ 21.24 (C-5,) 22.33 ( C-4' ', C-5"), 25.90 (C-3"), 43 〇 4 (c_ H 2,), 55.79 (C-7), 75.70 (C-l'), 111.43 (C-2 ), 116.99 (C-3,), 119.58 (C-3), 122.79 (C-6), 135.94 (C-2,), 137.50 (Cl), 139.59 (C-4), i511〇 (c_5), -1 69.90 (C-4'), 171.02 (Cl,,); molecular: • C17H2205. The fourth figure is based on the third example. TT inhibits lung cancer cell growth test results, Dehydrocos tus lactone For the other two substances Gloss〇gin A 5 4 9 the effect of suppressing the cancer cells are excellent, estimated I c 5. The values are 6. 6.27 and 48.49 pg/ml, respectively. - Example 4, fragrant grass column chromatography effectively distinguishes the product from inhibiting the growth of lung cancer cells - long-acting effect: A549 cells are effectively treated with fragrant grass for 24-48 hours, washed with phosphate buffer, and placed in 75 % ethanol was placed at 4 ° C overnight. Subsequently, the cells were washed twice with phosphate buffer, and the cells were suspended in phosphate buffer containing 40 pg/ml propidium iodide and 0.1 mg/ml RNase A, and treated at 37 ° C for 30 minutes. Finally, flow cytometry (flow) 17 201008572 • cytometer) to observe. As shown in the eighth figure, after the A549 cells are effectively treated by 15 column column chromatography, some of the cells will remain in the sub-Gl phase and no longer grow and multiply, so the fragrant grass has a distinction. The product causes lung cancer cells to die by apoptotic pathway. Moreover, the ratio of the number of A549 cells arrested in the sub-G1 phase increases with the treatment time. The dose of the product which effectively distinguishes the applied fragrant grass increases and increases (as shown in the figure). Example 5: Dehydrocostus lactone inhibitory effect of lung cancer cell growth: A549 cells were treated with Dehydrocostus lactone for 24 to 48'. The method described in Example 4 was used to observe the long period of A549 cells. influences. As shown in Figure IX, after treatment with - Dehydrocostus lactone, the growth cycle of some cells will be arrested in the sub-Gl phase and no longer grow and multiply. Therefore, the effective fractionation of the fragrant grass will lead to cell cycle of lung cancer cells. Death through the apoptotic pathway. Moreover, the ratio of the number of A549 cells stagnation in the sub-G1 phase also increases as the treatment time increases Ο 曰 and the dose of the effective sage is effectively increased (as shown in Fig. 2). - Example 6, the active ingredient of the geranium glossogin inhibits the growth of lung cancer cells: A549 cells are treated with Glossogin for 24 to 48 hours, and then the method described in Example 4 is used to observe the growth cycle of A 5 4 9 cells. Shadow. As shown in the tenth figure, after the treatment of GL〇SSOgin, the growth cycle of a cell will be stagnant in the sub-Gl phase and no longer grow and reproduce. The ring part 18 is labeled as above 201008572. • Therefore, the effective differentiation of the product by the scented grass can cause the lung cancer cells to die and die. Moreover, the increase in the number of A549 cells stagnant in the sub-G1 phase was associated with an increase in the effective differentiation of the applied fragrant grasses (as shown in Figure 7). π~Λ Ding Dan is also your ή and practicality. At the same time, it has been found in the technology of such techniques at home and abroad. It has not been found that the structure with the same approximation exists first, and should be named "progressive" "Combined with industrial use": and the patent requirements of «©" are submitted in accordance with the law. However, the above description is only a preferred embodiment of the present invention, and the application of the present specification and the scope of the patent application are all other equivalents, and are included in the invention. Will also follow the dose on the progress of the literature together with the "new creative deduction" method of the end of the knot 3 0 201008572. [Simplified schematic] The first series shows the chemical formula of Dehydrocostus lactone and Glossogin. The second series shows the inhibition ratio of the effective differentiation of the fragrant grass to the growth of A549 lung cancer cells. The third series shows the inhibition ratio of the Fragrant Grass Concentrate on the growth of A549 lung cancer cells. The fourth panel shows the inhibition ratio of two anti-cancer compounds of sage, A 5 49 lung cancer cell growth ® . The fifth series shows the ratio of cells treated with different doses of fragrant grass column chromatography to distinguish the A549 lung cancer cells from sub-G1 after 24 and 48 hours. The sixth series shows that A549 is treated with different doses of Dehydrocostus lactone. The ratio of cells in lung cancer cells that were arrested in the sub-G1 phase after 24 and 48 hours. The seventh series shows the ratio of cells in A 5 49 lung cancer cells treated with different doses of G1 〇 s s 〇 g i η, which persisted in the s u b - G1 phase after 24 and 48 hours. • The eighth series shows that A549 cells are effectively distinguished by the column chromatography of fragrant grasses. The ninth panel shows the results of treatment of A549 cells with Dehydrocostus lactone. The tenth series shows the results of treatment with Glossogin on A549 cells. [Main component symbol description] None 20

Claims (2)

201008572 .十、申請專利範圍: 1. 一種香茹草抗肺癌物質,其係包含有以下成分: Dehydrocostus lactone :201008572 . X. Patent application scope: 1. A fragrant grass anti-lung cancer substance, which contains the following ingredients: Dehydrocostus lactone: 6-Hydroxy-guaia-4(15),10(14),11(13)-trien-12- 〇ic acid lactone ; Glossogin : 1 ^ce^〇xy~4-〇-is〇valyryleugenol ° 2.依據中請專利H圍第i項所述之香$草抗肺癌物質,其中 β ,該香知草抗肺癌物質係可單獨使用。 3·依據巾請專利範圍第1項所述之香$草抗肺癌物質,其中 ’該香知草抗肺癌物質係可混合使用。 4.依據申請專利範圍第1項所述之香⑪草抗肺癌物質,其中 . ,該香茹草抗肺癌物質係可以組成物方式使用。 5_ —種香茹草抗肺癌物質的製備方法,其包含有: (a) 將香茹草利用水或有機溶劑萃取,得到香茹草粗萃物; (b) 2驟(a)所得香|草粗萃物透過其他不同有機溶劑進 行萃取,以得到香茹草萃取物; -⑷令步驟⑻所得香兹草萃取物使用石夕膠管柱層析進行八 ' 離,以得到香茹草有效成份區分物; 刀 (d) 7步驟(c)所知香茹草有效成份區分物使用冑備型言 液相層析管柱進行純化分離’俾得到㈣仏咖… lactone和Glossogin等兩種抗肺癌活性物質。 6.依據巾請專利範圍第5項所述之衫草抗肺癌物質的 方法’其中’步驟(a)所用以萃取製造香祐草粗萃物之有 21 201008572 . 機溶劑係為乙醇和子醇。 7. 依據申請專利範圍第5項所述之香 方法,其令,步驟(b)# a . 草抗肺癌物質的製備 诹所用以萃取製造香茹 機溶劑為乙酸乙酯。 卓卓取物之有 8. 依據申請專利蔚圖笛c 方法,其中,步驟$項所述之㈣草抗肺癌物質的製備 . 步驟(c)所用以製造香茹草有#^「 之層析管柱填充物為Si,石夕膠。 心區分物 9 ·依據申請專利筋圍笛κ = ❹ J範圍第5項所述之香兹草抗肺癌物 方法,其中,舟聰投備 之廢械4叔 驟(C)所用以製造香兹草有效成份區分物 層斤流動相為正己烷和乙酸乙酯。 10. 依據申清專利銘图哲 j範圍第5項所述之香$草抗肺癌物f的製備 / /、步驟(C)所用以製造香茹草有效成份區分物 之層析分離步驟包括一至多次層析分離操作。 11. 依據申請專利範圍第5項所述之香$草抗肺癌物質的製備 ❹ 方法,其中,步驟(d)所用以製造香茹草抗癌物質之高效 液相層析管柱為正相矽膠管柱。 门 12. 依據申請專利範圍第5項所述之香茹草抗肺癌物質的製備 方法’其中,步驟(d)所用以製造香茹草抗癌物質之高效 液相層析流動相為正己烷和乙酸乙酯。 226-Hydroxy-guaia-4(15),10(14),11(13)-trien-12- 〇ic acid lactone ; Glossogin : 1 ^ce^〇xy~4-〇-is〇valyryleugenol ° 2.According to In the patent H, the incense of the grass is the anti-lung cancer substance, wherein β, the Xiangzhi grass anti-lung cancer substance can be used alone. 3. According to the towel, please note that the fragrant grass of the patent scope is the anti-lung cancer substance, wherein the scented anti-lung cancer substance can be used in combination. 4. According to the patent application scope of claim 1, the fragrant 11 grass anti-lung cancer substance, wherein the fragrant grass anti-lung cancer substance can be used as a composition. 5_ - A method for preparing a succulent herb against lung cancer, comprising: (a) extracting the fragrant grass with water or an organic solvent to obtain a crude extract of fragrant grass; (b) obtaining the fragrant scent of (a) The crude extract of the grass is extracted by other different organic solvents to obtain the extract of the fragrant grass; - (4) the extract of the fragrant grass obtained in the step (8) is subjected to the separation of the stalks of the stalks to obtain the active ingredients of the fragrant grasses. Distinguishment; Knife (d) 7 Step (c) Known that the active ingredient of the fragrant grass is purified and separated using a preparative type of liquid chromatography column. '俾(4) 仏咖... lactone and Glossogin and other two anti-lung cancer Active substance. 6. The method for extracting the crude extract of the scented scented grass according to the method of claim 5, wherein the step (a) is used for extracting the crude extract of the scented scented grass. 21 201008572. The solvent is ethanol and a sub-alcohol. 7. According to the fragrant method described in claim 5, the step (b)# a. Preparation of grass anti-lung cancer substance 诹 The solvent used for the extraction and preparation of fragrant machine is ethyl acetate. According to the patent application of the Tutu flute c method, the preparation of the (4) grass anti-lung cancer substance described in the step (c) is used to produce the fragrant grass with #^" The column packing is Si, Shishijiao. Heart division 9 · According to the patent application gluten κ = ❹ J range item 5 according to the method of the zizi grass anti-lung cancer method, wherein the fishing equipment of Zhou Cong 4 Unsuccessful (C) used to make the active component of the Fraxin grass substance, the mobile phase of the layer is n-hexane and ethyl acetate. 10. According to the application of the patent of Mingqing Patent Mingtuzhe scope 5, the grass is anti-lung cancer The chromatographic separation step for preparing the substance f and/or the step (C) for producing the active ingredient of the fragrant grass comprises one or more chromatographic separation operations. 11. According to the patent claim 5 The method for preparing an anti-lung cancer substance, wherein the high-performance liquid chromatography column for producing the anti-cancer substance of the sage grass in the step (d) is a normal phase rubber tube column. The door is according to the fifth aspect of the patent application. Method for preparing anti-lung cancer substance of fragrant grasses, wherein step (d) is used High performance liquid chromatography flow mushroom grass anticancer substances phase of n-hexane and ethyl acetate. 22
TW97131705A 2008-08-20 2008-08-20 Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same TW201008572A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW97131705A TW201008572A (en) 2008-08-20 2008-08-20 Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW97131705A TW201008572A (en) 2008-08-20 2008-08-20 Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same

Publications (2)

Publication Number Publication Date
TW201008572A true TW201008572A (en) 2010-03-01
TWI392500B TWI392500B (en) 2013-04-11

Family

ID=44827537

Family Applications (1)

Application Number Title Priority Date Filing Date
TW97131705A TW201008572A (en) 2008-08-20 2008-08-20 Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same

Country Status (1)

Country Link
TW (1) TW201008572A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI484914B (en) * 2013-11-21 2015-05-21 Jer Yiing Houng A usage of an extract of glossogyne tenuifolia for inhibiting growth of aeromonas hydrophila and vibrio vulnificus
TWI634894B (en) * 2017-09-30 2018-09-11 國立澎湖科技大學 Extraction process for glossogyne tenuifolia and pharmaceutical composition containing glossogyne tenuifolia extract for inhibiting growth of prostate cancer cells
CN110755463A (en) * 2018-07-25 2020-02-07 东海大学 Uses of fenugreek extract

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69620013T2 (en) * 1995-12-11 2002-08-22 Lord Corp., Cary COMPOSITIONS CONTAINING MODIFIED POLYALCADIENES

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI484914B (en) * 2013-11-21 2015-05-21 Jer Yiing Houng A usage of an extract of glossogyne tenuifolia for inhibiting growth of aeromonas hydrophila and vibrio vulnificus
TWI634894B (en) * 2017-09-30 2018-09-11 國立澎湖科技大學 Extraction process for glossogyne tenuifolia and pharmaceutical composition containing glossogyne tenuifolia extract for inhibiting growth of prostate cancer cells
CN110755463A (en) * 2018-07-25 2020-02-07 东海大学 Uses of fenugreek extract

Also Published As

Publication number Publication date
TWI392500B (en) 2013-04-11

Similar Documents

Publication Publication Date Title
CN104688782B (en) A kind of method of the high efficiency extraction triterpene active component from fuling peel
CN104341430B (en) A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes
Barcellona et al. Safety assessment of aqueous extract from leaf Smallanthus sonchifolius and its main active lactone, enhydrin
CN104292278B (en) Myrobalan tannin compounds, and preparation method and applications thereof
CN101007050A (en) Extract of an traditional Chinese medicine containing isopsoralen, preparation method and use thereof
CN107669665B (en) Application of 5-pentyl-3-methoxy-phenol in the preparation of oxidative stress or inflammatory response-induced disease prevention products
CN101979366A (en) Diphenylheptane compounds in zedoary and their medicinal uses
CN102335165A (en) Application of flavonoids compounds to breast cancer resistance
CN102516344A (en) Compound with antitumor activity and preparation method and application thereof
TW201008572A (en) Anti-lung cancer Glossogyne tenuifolia substance and method of preparing the same
CN103565781B (en) Composite, preparation thereof and application of composite in preparing antidepressant drug
CN102659802B (en) Application in terms of the preparation method of coumarin Neolignans and anti-marime fouling thereof
CN109942649B (en) Indole glycoside compound and extraction and separation method and application thereof
Liu et al. Immunomodulatory effects of epicatechin-(2 β→ O→ 7, 4 β→ 8)-ent-epicatechin isolated from Rhododendron spiciferum in vitro
CN107298642A (en) A kind of method for extraction and purification of 6 salad oil
CN104151392A (en) Moebioside A as well as preparation and application thereof
CN104138368A (en) Preparation method and cancer treatment effect of Rhizoma Alpiniae Officinarum aboveground part AO-95
CN103833818B (en) The antitumor drug of a kind of Sasanguasaponin compound, its preparation method, application and preparation thereof
CN116735776A (en) Method for simultaneously detecting isosorbide and rosmarinic acid in selfheal seeds and application of method
CN114533719A (en) Application of abietane diterpenoid compound in preparation of anti-inflammatory drugs
CN116655717B (en) Separation and purification method of two phenolic compounds from Polygonum capitatum and its application
CN115040554B (en) Application of wu Su Liwa Wei Zonghuang ketone
Zidan et al. Bioactive butanolides and steroids from the Red Sea soft coral Sarcophyton ehrenbergi
CN105418725B (en) Pentacyclic triterpenoid and its application
CN118930420B (en) A sesquiterpenoid compound and its preparation method and application

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees